{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:45:30Z","timestamp":1770741930197,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Center for Applied Genomics & Precision Medicine"},{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007101"],"award-info":[{"award-number":["5T32HL007101"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["5UL1RR024128"],"award-info":[{"award-number":["5UL1RR024128"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institutes of General Medical Sciences","doi-asserted-by":"crossref","award":["5RC1GM091083"],"award-info":[{"award-number":["5RC1GM091083"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung \u2026 Blood Institute","doi-asserted-by":"publisher","award":["5R01HL118049"],"award-info":[{"award-number":["5R01HL118049"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5U01DD000014"],"award-info":[{"award-number":["5U01DD000014"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"David H. Murdock Research Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Gene expression biosignatures may hold promise to individualize antiplatelet therapy in conjunction with current guidelines and risk scores. The Aspirin Response Signature (ARS) score is comprised of a weighted sum of correlated, pro-thrombotic gene transcripts measured in whole blood. In prior work where volunteers were exposed to aspirin 325 mg daily, higher ARS score was associated with lower platelet function; separately, in a clinical cohort of patients, higher ARS scores were associated with increased risk of adverse cardiovascular events. To better understand this apparent paradox, we measured ARS gene expression and score in volunteers to determine aspirin dose\u2013response and ticagrelor relationships with ARS score and separately in patients to assess whether ARS is associated with incident bleeding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Blood samples were collected from volunteers (N = 188) who were exposed to 4 weeks of daily aspirin 81 mg, daily aspirin 325 mg, and\/or twice-daily ticagrelor 90 mg. ARS scores were calculated from whole blood RNA qPCR, and platelet function and protein expression were assessed in platelet-rich plasma. In mixed linear regression models, aspirin 81 mg exposure was not associated with changes in ARS gene expression or score. Aspirin 325 mg exposure resulted in a 6.0% increase in ARS gene expression (P = 7.5 \u00d7 10\u22129 vs. baseline, P = 2.1 \u00d7 10\u22124 vs. aspirin 81 mg) and an increase in expression of platelet proteins corresponding to ARS genes. Ticagrelor exposure resulted in a 30.7% increase in ARS gene expression (P &amp;lt; 1 \u00d7 10\u221210 vs. baseline and each aspirin dose) and ARS score (P = 7.0 \u00d7 10\u22127 vs. baseline, P = 3.6 \u00d7 10\u22126 and 5.59 \u00d7 10\u22124 vs. aspirin 81 and 325 mg, respectively). Increases in ARS gene expression or score were associated with the magnitude of platelet inhibition across agents. To assess the association between ARS scores and incident bleeding, ARS scores were calculated in patients undergoing cardiac catheterization (N = 1421), of whom 25.4% experienced bleeding events over a median 6.2 years of follow-up. In a Cox model adjusting for demographics and baseline antithrombotic medication use, patients with ARS scores above the median had a higher risk of incident bleeding [hazard ratio 1.26 (95% CI 1.01\u20131.56), P = 0.038].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The ARS is an Antiplatelet Response Signature that increases in response to greater platelet inhibition due to antiplatelet therapy and may represent a homeostatic mechanism to prevent bleeding. ARS scores could inform future strategies to prevent bleeding while maintaining antiplatelet therapy\u2019s benefit of ischaemic cardiovascular event protection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cvr\/cvac079","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T19:10:46Z","timestamp":1652123446000},"page":"551-560","source":"Crossref","is-referenced-by-count":3,"title":["An antiplatelet response gene expression signature is associated with bleeding"],"prefix":"10.1093","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5075","authenticated-orcid":false,"given":"Kevin A","family":"Friede","sequence":"first","affiliation":[{"name":"Center for Applied Genomics & Precision Medicine, Duke University , 101 Science Dr, DUMC 3382, Durham, NC , USA"},{"name":"Division of Cardiology, Duke University , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A","family":"Myers","sequence":"additional","affiliation":[{"name":"Center for Applied Genomics & Precision Medicine, Duke University , 101 Science Dr, DUMC 3382, Durham, NC , USA"},{"name":"Division of Cardiology, Duke University , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Gales","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Texas Heart Institute , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6502-6514","authenticated-orcid":false,"given":"Ilya","family":"Zhbannikov","sequence":"additional","affiliation":[{"name":"Center for Applied Genomics & Precision Medicine, Duke University , 101 Science Dr, DUMC 3382, Durham, NC , USA"},{"name":"Division of Cardiology, Duke University , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L","family":"Ortel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Duke University , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svati H","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University , Durham, NC , USA"},{"name":"Duke Molecular Physiology Institute, Duke University , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1930-9684","authenticated-orcid":false,"given":"William E","family":"Kraus","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University , Durham, NC , USA"},{"name":"Duke Molecular Physiology Institute, Duke University , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-9808","authenticated-orcid":false,"given":"Geoffrey S","family":"Ginsburg","sequence":"additional","affiliation":[{"name":"All of Us Research Program, National Institutes of Health , Bethesda, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5179","authenticated-orcid":false,"given":"Deepak","family":"Voora","sequence":"additional","affiliation":[{"name":"Center for Applied Genomics & Precision Medicine, Duke University , 101 Science Dr, DUMC 3382, Durham, NC , USA"},{"name":"Division of Cardiology, Duke University , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"2023052918400621700_cvac079-B1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2023052918400621700_cvac079-B2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2023052918400621700_cvac079-B3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"key":"2023052918400621700_cvac079-B4","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2023052918400621700_cvac079-B5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2023052918400621700_cvac079-B6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"2023052918400621700_cvac079-B7","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1093\/eurheartj\/ehz823","article-title":"Antithrombotic therapy after acute coronary syndrome and\/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot","volume":"40","author":"Lopes","year":"2019","journal-title":"Eur Heart J"},{"key":"2023052918400621700_cvac079-B8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of antithrombotic therapy after acute coronary syndromes","volume":"384","author":"Rodriguez","year":"2021","journal-title":"N Engl J Med"},{"key":"2023052918400621700_cvac079-B9","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"2023052918400621700_cvac079-B10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"2023052918400621700_cvac079-B11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(20)32519-8","article-title":"Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets","volume":"397","author":"D\u2019Ascenzo","year":"2021","journal-title":"Lancet"},{"key":"2023052918400621700_cvac079-B12","doi-asserted-by":"crossref","first-page":"e014726","DOI":"10.1161\/JAHA.119.014726","article-title":"Influence of sex on platelet reactivity in response to aspirin","volume":"9","author":"Friede","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023052918400621700_cvac079-B13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11239-020-02327-w","article-title":"Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans","volume":"51","author":"Infeld","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2023052918400621700_cvac079-B14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1160\/TH10-04-0232","article-title":"Impact of race and gender on antithrombotic therapy","volume":"104","author":"Capodanno","year":"2010","journal-title":"Thromb Haemost"},{"key":"2023052918400621700_cvac079-B15","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"2023052918400621700_cvac079-B16","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"2023052918400621700_cvac079-B17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacc.2013.05.073","article-title":"Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events","volume":"62","author":"Voora","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023052918400621700_cvac079-B18","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1111\/bcp.15127","article-title":"Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function","volume":"88","author":"Myers","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2023052918400621700_cvac079-B19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11239-012-0683-0","article-title":"Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy","volume":"33","author":"Voora","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"2023052918400621700_cvac079-B20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/202095b0","article-title":"Strong inhibition by 2-chloroadenosine of the aggregation of blood platelets by adenosine diphosphate","volume":"202","author":"Born","year":"1964","journal-title":"Nature"},{"key":"2023052918400621700_cvac079-B21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12265-015-9648-y","article-title":"A guide for a cardiovascular genomics biorepository: the CATHGEN experience","volume":"8","author":"Kraus","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"key":"2023052918400621700_cvac079-B22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"2023052918400621700_cvac079-B23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jcin.2012.05.010","article-title":"Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients","volume":"5","author":"Rao","year":"2012","journal-title":"JACC Cardiovascular Interv"},{"key":"2023052918400621700_cvac079-B24","doi-asserted-by":"crossref","first-page":"e1005553","DOI":"10.1371\/journal.pgen.1005553","article-title":"Metabolomic Quantitative Trait Loci (mQTL) mapping implicates the ubiquitin proteasome system in cardiovascular disease pathogenesis","volume":"11","author":"Kraus","year":"2015","journal-title":"PLoS Genet"},{"key":"2023052918400621700_cvac079-B25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11239-017-1516-y","article-title":"Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome","volume":"44","author":"Lowenstern","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"2023052918400621700_cvac079-B26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: biological basis, clinical use and new drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2023052918400621700_cvac079-B27","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/2221269a0","article-title":"Platelet factor 4 and adenosine diphosphate release during human platelet aggregation","volume":"222","author":"Niewiarowski","year":"1969","journal-title":"Nature"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvac079\/44318318\/cvac079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/119\/2\/551\/50482709\/cvac079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/119\/2\/551\/50482709\/cvac079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T18:40:34Z","timestamp":1685385634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/119\/2\/551\/6586504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,5,16]]},"published-print":{"date-parts":[[2023,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvac079","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,5,16]]}}}